AMENDMENT

Amendments to the Claims:

Please amend the claims as follows, without prejudice:

In the Claims:

1-45 (Canceled).

46. (Currently Amended) A ~~S~~serum-stable amphoteric liposomal formulation[[s]] comprising a liposome with an aqueous interior and at least one active substance in the aqueous interior, ~~characterized in~~

~~that~~ wherein the liposomes comprise

- neutral lipids with a membrane proportion of 10 to 60 mole-%,
- cholesterol with a proportion of 30 to 50 mole-%,

and, as charged lipids, either

- amphoteric lipids with a proportion of 5 to 30 mole-%,

or

- mixtures of cationic and anionic lipids with an overall proportion of 50 mole% at maximum,

and ~~that~~ wherein the active substance comprises at least one oligonucleotide.

47. (Currently Amended) The liposomal formulation according to claim ~~1~~46, ~~characterized in that~~ wherein the proportion of cholesterol is 35 to 45 mole-%[[,]] and the proportion of amphoteric lipids is 5 to 20 mole-% ~~and/or the proportion of said mixtures is 15 to 45 mole-%~~.

48. (Currently Amended) The liposomal formulation according to claim ~~1~~46, ~~characterized in that~~ wherein the oligonucleotides are constituted of 5-100~~, preferably 5-40 and more preferably 10-25~~ deoxyribonucleotides, ribonucleotides or chemically modified derivatives thereof.

49. (Currently Amended) The liposomal formulation according to claim ~~1~~46, ~~characterized in that~~ wherein the oligonucleotides are present as single strands, double strands, or in complex folding.

50. (Currently Amended) The liposomal formulation according to claim 46, ~~characterized in that~~ wherein the ~~single strands are present as~~ oligonucleotide is an antisense oligonucleotides~~, the double strands as small interfering RNA and/or decoy oligonucleotides and/or the complex foldings as aptamers and/or spiegelmers~~.

51. (Currently Amended) The liposomal formulation according to claim ~~1~~46, ~~characterized in that~~ wherein the oligonucleotide is an aptamer.

52. (Currently Amended) The liposomal formulation according to claim ~~1~~46, ~~characterized in that~~ wherein the oligonucleotide is a spiegelmer.

53. (Currently Amended) The liposomal formulation according to claim ~~1~~46, ~~characterized in that~~ wherein the ~~liposomal membrane~~ liposome has ~~the~~ a molar composition selected from the group consisting of:

DMPC/MoChol/DMPS/Chol 40:10:10:40,
DMPC/AC/Chol 50:10:40,
DMPC/HisChol/DPPS/Chol 35:10:15:40,
DMPC/IsohistsuccDG/Chol 50:10:40,
DMPC/MoChol/DGSucc/Chol 35:10:15:40,
DMPC/MoChol/DGSucc/Chol 40:10:10:40,
POPC/MoChol/DGSucc/Chol 35:10:15:40,
DMPC/HistSuccDG/Chol 50:10:40,
POPC/MoChol/DPPS/Chol 40:10:10:40,
DPPC/DOTAP/DGSucc/Chol 20:10:30:40,
DPPC/HistChol/Chol 50:10:40,

DPPC/HistSuccDG/Chol 40:20:40,
DPPC/MoChol/DGSucc/Chol 20:10:30:40,
POPC/HcChol/Chol 50:15:35,
DPPC/HcChol/Chol 50:15:35,
POPC/HistPS/Chol 50:15:35,
DPPC/HistPS/Chol 50:15:3 5,
POPC/AC/Chol 50:15:35,
DPPC/AC/Chol 50:15:35,
DPPC/HistChol/Chol 50:15:35,
POPC/HistChol/Chol 50:15:35,
DMPC/MoChol/DGSucc/Chol 20:10:30:40,
POPC/HistSuccDG/Chol 50:15:35,
DPPC/IsoHistSuccDG/Chol 50:15:35,
DPPC/HistSuccDG/Chol 50:15:35,
POPC/IsoHistSuccDG/Chol 50:15:35,
DMPC/MoChol/DGSucc/Chol 20:10:30:40,
POPC/MoChol/CHEMS/Chol 40:10:10:40,
DMPC/HistChol/Chol 50:10:40,
POPC/DOTAP/CHEMS/Chol 30:10:20:40,
DMPC/HisChol/DGSucc/Chol 40:10:10:40,
POPC/HisChol/CHEMS/Chol 40:10:10:40,
DMPC/MoChol/CHEMS/Chol 40:10:10:40 ~~or~~and
POPC/MoChol/DGSucc/Chol 30:20:10:40.

54. (Currently Amended) A method of treating a mammal with a drug comprising administering to the mammal the drug in the liposomal formulation[[s]] of claim ~~1~~46.

55. (Currently Amended) The method of claim ~~9~~54 wherein the mammal is a human.

56. (Currently Amended) The method of claim 954 wherein the liposomal formulation is administered parenterally~~for parenteral application, preferably intravenous application~~.

57. (Currently Amended) The method of claim 954, ~~characterized in that it~~ wherein the liposomal formulation includes one or more active substances.

58. (New) The liposomal formulation according to claim 46, wherein the proportion of cholesterol is 35 to 45 mole-% and the proportion of said mixtures is 15 to 45 mole-%.

59. (New) The liposomal formulation according to claim 46, wherein the oligonucleotide is a small interfering RNA.

60. (New) The liposomal formulation according to claim 46, wherein the oligonucleotide is a decoy oligonucleotide.